ArticleBiomaterials2021
Bone targeting nanocarrier-assisted delivery of adenosine to combat osteoporotic bone loss.
Article in Biomaterials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- The miR-212-3p/transferrin axis promotes bone regeneration by modulating iron homeostasis through Schwann cell Exosome-BMSCs communication.Bioactive materials · 2026Article
- Hybrid extracellular vesicles for targeted delivery of therapeutic cargoes to combat osteoporotic bone loss.Cell biomaterials · 2026Article
- Alendronic acid modified PLGA drug delivery system loaded with 17β-Estradiol and vitamin D3 has anti-osteoporotic effect.Materials today. Bio · 2026Article
- Piezo1-activated mesenchymal stem cells-derived extracellular matrix hydrogel promotes the repair of osteoporotic bone defects through osteogenic and angiogenic coupling.Regenerative biomaterials · 2026Article
- Recent advances in biomimetic nanodelivery systems for the treatment of osteoporosis.Materials today. Bio · 2025Review
- Loss of Brd4 alleviates pathological bone loss via Slc9b2 suppression in osteoclastogenesis.Clinical and translational medicine · 2025Article
- Innovative nanocarriers: Synthetic and biomimetic strategies for enhanced drug delivery.Materials today. Bio · 2025Review
- Enabling adenosine signaling to promote aged fracture healing.NPJ Regenerative medicine · 2025Article
- Versatile and Marvelous Potentials of Polydeoxyribonucleotide for Tissue Engineering and Regeneration.Biomaterials research · 2025Review
- Ångstrom-scale gold particles loaded with alendronate via alpha-lipoic acid alleviate bone loss in osteoporotic mice.Journal of nanobiotechnology · 2024Article
- Bone Targeting Nanoparticles for the Treatment of Osteoporosis.International journal of nanomedicine · 2024Review
- Multi-Functional Small Molecule Alleviates Fracture Pain and Promotes Bone Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Radiation-induced bone loss in mice is ameliorated by inhibition of HIF-2α in skeletal progenitor cells.Science translational medicine · 2023Article
- Emerging nano-scale delivery systems for the treatment of osteoporosis.Biomaterials research · 2023Review
- Extracellular adenosine signaling in bone health and disease.Current opinion in pharmacology · 2023Review
- Rational polyelectrolyte nanoparticles endow preosteoclast-targeted siRNA transfection for anabolic therapy of osteoporosis.Science advances · 2023Article
- Microgel-Assisted Delivery of Adenosine to Accelerate Fracture Healing.ACS biomaterials science & engineering · 2022Article
- pH-Sensitive nanocarrier assisted delivery of adenosine to treat osteoporotic bone loss.Biomaterials science · 2022Article
- Recrystallization of Adenosine for Localized Drug Delivery.Molecular pharmaceutics · 2022Article
- Bone targeting antioxidative nano-iron oxide for treating postmenopausal osteoporosis.Bioactive materials · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Extracellular adenosine has been shown to play a key role in maintaining bone health and could potentially be used to treat bone loss. However, systemic administration of exogenous adenosine to treat bone disorders remains a challenge due to the ubiquitous presence of adenosine receptors in different organs and the short half-life of adenosine in circulation. Towards this, we have developed a bone-targeting nanocarrier and determined its potential for systemic administration of adenosine. The nanocarrier, synthesized via emulsion suspension photopolymerization, is comprised of hyaluronic acid (HA) copolymerized with phenylboronic acid (PBA), a moiety that can form reversible bonds with adenosine. The bone binding affinity of the nanocarrier was achieved by alendronate (Aln) conjugation. Nanocarriers functionalized with the alendronate (Aln-NC) showed a 45% higher accumulation in the mice vertebrae in vivo compared to those lacking alendronate molecules (NCs). Systemic administration of adenosine via bone-targeting nanocarriers (Aln-NC) attenuated bone loss in ovariectomized (OVX) mice. Furthermore, bone tissue of mice treated with adenosine-loaded Aln-NC displayed trabecular bone characteristics comparable to healthy controls as shown by microcomputed tomography, histochemical staining, bone labeling, and mechanical strength. Overall, our results demonstrate the use of a bone-targeting nanocarrier towards systemic administration of adenosine and its application in treating bone degenerative diseases such as osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.